Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study

Hepatitis

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study

Lancet

Noureddin M, Harrison SA, Loomba R, Alkhouri N, Chalasani N, Sheikh MY, Tomah S, Gutierrez JA, Urbina S, Suschak JJ, Brown R, Odili O, Yang J, Keeton S, Neff G, Mena E, Roberts MS, Browne SK, Harris MS

doi: 10.1016/S0140-6736(25)02114-2

Gastrointestinal Cancer

Quantitative spatial profiling of PD-1/PD-L1 and TIGIT/CD155 interaction indicates poor survival outcome and resistance to adjuvant chemotherapy in pancreatic adenosquamous carcinoma

Eur J Cancer

Chen X, Sun S, Li S, Yu S, Chen J, Chen X, Shi X, Liang Z

doi: 10.1016/j.ejca.2025.116159

Gastrointestinal Cancer

Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study

Lancet

Shen L, Zhang X, Ji K, Lu L, Wang Q, Guan Q, Yan S, Zhou Y, Yang Y, Huo Z, You J, Ba Y, Ye Y, Chen Y, Wang S, Lv G, Zhang J, Hu X, Yang F, Yu H, Li J, Wang Q, Zhu J, Ji J, ASTRUM-006 Study Group

doi: 10.1016/S0140-6736(26)00974-8

Further Publications

Impact of initial severity and progression pattern of new-onset diabetes on pancreatic cancer risk: a 15-year longitudinal nationwide cohort study

Gut

Lee M, Yu MH, Chae W, Lee YH, Lee BW, Kang ES, Cha BS, Jang SI, Chung MJ

doi: 10.1136/gutjnl-2025-335863

Inflammatory Bowel Disease

Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg

J Crohns Colitis

De Greef E, Turner D, Kierkuś J, Korczowski B, Meglicka M, Cohen SA, Hyams JS, Griffiths AM, Rosh JR, Strauss R, Van Limbergen E, Adedokun OJ, Kim L, Volger S, UNITI Jr study Group

doi: 10.1093/ecco-jcc/jjag011

Gastrointestinal Cancer

Metastatic pancreatic adenocarcinoma: Real-world efficacy of first line treatment

Eur J Cancer

Debiais M, Tarabay A, Blanchet-Deverly S, Camilleri GM, Megherbi A, Diebakate L, Collin M, Hollebecque A, Smolenschi C, Valéry M, Pudlarz T, Fuerea AC, Boige V, Ducreux M, Boilève A

doi: 10.1016/j.ejca.2025.116160

Inflammatory Bowel Disease

Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study

Inflamm Bowel Dis

Turner D, Lomax KG, Veereman G, Griffiths AM, Kierkuś J, Kang B, Berezny K, Padgett L, Mao G, Zitser Y, Strauss RS, Verhoeven J, Adedokun OJ, Hyams JS

doi: 10.1093/ibd/izaf322

Gastrointestinal Cancer

First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF(V600E)-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)

Eur J Cancer

Weiss L, Stintzing S, Modest DP, Stahler A, von Weikersthal LF, Reinacher-Schick A, Decker T, Probst V, Heinrich K, Schwaner I, Kaiser F, Pihusch R, Fuchs M, Held S, Alig A, Gruenberger B, Prager GW, Tougeron D, Taieb J, Heinemann V

doi: 10.1016/j.ejca.2025.116105

Inflammatory Bowel Disease

Efficacy and Safety of Risankizumab in Patients with Moderately to Severely Active Crohn's Disease: Interim Results from the SEQUENCE Open-Label Extension Study

J Crohns Colitis

Peyrin-Biroulet L, Atreya R, Danese S, Lindsay JO, Chapman JC, Anschutz T, Huang X, Zambrano J, van Haaren S, Joshi N, Duan WR, Cross RK

doi: 10.1093/ecco-jcc/jjaf213

Related content

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study

Quantitative spatial profiling of PD-1/PD-L1 and TIGIT/CD155 interaction indicates poor survival outcome and resistance to adjuvant chemotherapy in pancreatic adenosquamous carcinoma

Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study

Impact of initial severity and progression pattern of new-onset diabetes on pancreatic cancer risk: a 15-year longitudinal nationwide cohort study

Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg

Metastatic pancreatic adenocarcinoma: Real-world efficacy of first line treatment

Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study

First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF(V600E)-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)

Efficacy and Safety of Risankizumab in Patients with Moderately to Severely Active Crohn's Disease: Interim Results from the SEQUENCE Open-Label Extension Study